MagSense™ FR Imaging Agent
Ovarian Cancer
Pre‑clinicalActive
Key Facts
About Imagion Biosystems
Imagion Biosystems delivers targeted, radiation‑free molecular MRI for earlier, more precise cancer detection.
View full company profileTherapeutic Areas
Other Ovarian Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| EXO‑Ovarian Cancer Test | INOVIQ | Phase 2/3 |
| CAR‑iNK‑OvCa | Cartherics | Preclinical |
| Yondelis (trabectedin) | PharmaMar | Approved |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| NP-G2-044 + Chemotherapy Agents | Novita Pharmaceuticals | Phase 2a |
| Ivospemin (SBP-101) | Panbela Therapeutics | Phase 2 |
| Ovarian Cancer Early Detection Assay | GenEndeavor | Pre-clinical |
| INVAC-1 | Invectys | Phase 2 |
| Folate Receptor-Targeted PCC | Indi Molecular | Preclinical |
| Immunomodulator Platform | OmniCyte | Pre-clinical |
| Platform Candidate | FLAG Therapeutics | Preclinical |
| High Internalization ADC | Lytica Therapeutics | Preclinical |